Tag Archives: BIO CEO & Investor Conference

Business Roundtable: The Reimbursement Landscape under ACA

Capture

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one of the most pressing issues facing healthcare stakeholders and decision makers, including patients, payers, providers, and innovative drug developers. BIO hosted a business roundtable discussion on this timely topic yesterday at our 16th Annual BIO CEO & Investor Conference. Moderated by Real Endpoint’s Roger Longman, panelists represented a variety of perspectives: Peter Bach, MD, MAPP, Attending Physician, Memorial Sloan-Kettering Cancer Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

#BIOCEO14: An Optimistic Outlook for 2014

Panel

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining the current capital market for IPOs, where the industry has been and where it’s headed in 2014. The panel unanimously agreed: 2013 was the year of the IPO. In total, 56 healthcare companies priced an IPO; 43 of these were biotech companies. Last year was the strongest IPO year since 2000 and the second strongest in history with over $10 Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Fireside Chat with Allergan CEO, David Pyott

David Pyott

Day two of the 16th Annual BIO CEO & Investor Conference​ kicked off with a Fireside Chat featuring one of the longest tenured pharma CEOs, David E.I. Pyott, Chairman of the Board & Chief Executive Officer, Allergan. The Chat, moderated by Seamus Fernandez, Managing Director, Major and Specialty Pharmaceuticals, Leerink Partners LLC, explored the multi-specialty healthcare model that Allegran has found success in which few realize is not just ophthalmology. Allergan has also found success in neurosciences, medical dermatology, dermal fillers and urologics. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Open Communication Helps Reduce Rare Disease Drug Development Risk

115x76allisonMparks

One of the most important keys to successful relationships – be it in life or rare disease drug development – is open, honest and frequent communication, according to a panel of rare disease experts speaking at the Therapeutic Workshop: “Balancing the Rick-Reward in Rare Disease Drug Development” at the BIO CEO & Investor Conference in New York on Monday. Without engaging the key groups at the right time and the right manner, companies entering this Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Sanofi’s Chris Viehbacher: Trust, Respect Key in Pharma-Biotech Partnerships

33713_Viehbacher_100x100 copy

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the strengths of each side in order to bring new therapies to patients? Sanofi CEO and Genzyme Chairman Chris Viehbacher shared his thoughts on that question and several other topics, including the growing importance of emerging markets, at a Fireside Chat at the 16th Annual BIO CEO & Investor Conference on Monday. He reflected that as the leader of a big pharma Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,